The Temple Lung Center conducts one of the most comprehensive lung disease clinical trials programs in the country. Our advancements in basic, translational and clinical research are changing lung disease treatment. By pioneering effective therapies, we bring hope to patients with serious and debilitating lung diseases. 

 

ALA-ACRC "Improving Medication Adherence with Telehealthcare Medication Therapy Management to Change Health Outcomes in Adolescents and Young Adults with Asthma" (MATCH) Trial

 

A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype (NIMBLE)
NCT04718389

 

Effectiveness and Safety Study of Tezepelumab in Adults & Adolescent Participants With Severe Asthma in the United States (PASSAGE)
NCT05329194

A Phase III, Extension Clinical Trial to Demonstrate Efficacy and Safety of Liposomal Cyclosprine A Via the PARI Investigational eFlow® Device and SoC in Treating Bronchiolitis Obliterans in Patients Post Single or Double Lung Transplant (BOSTON-3)

 

 

Bronchiectasis

 

 

Chronic Bronchitis

 

A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Mepolizumab 100mg SC as add-on Treatment in Participants With COPD Experiencing Frequent Exacerbations and Characterized by Eosinophil Levels (MATINEE)

 

Roflumilast or Azithromycin to Prevent COPD Exacerbations (RELIANCE)
NCT04069312

 

Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations (RESOLUTE)
NCT04053634

 

Evaluation of the Safety and Efficacy of TLD in Patients With COPD (AIRFLOW-3)
NCT03639051

 

Predicting Sleep, Smoking, and Lung Health Disparities in African American Adults
NCT03534076

 

A Sham Controlled Prospective Randomized Clinical Trial of the RejuvenAir System for the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease with Chronic Bronchitis (Spray-CB)
NCT03893370

 

Clinical Study of the RheOx Bronchial Rheoplasty System in Treating the Symptoms of Chronic Bronchitis (RheSolve)
NCT04677465

 

A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess MEDI3506 in Participants With COPD and Chronic Bronchitis (FRONTIER-4)
NCT04631016

 

A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter Phase 2a Study to Explore the Efficacy and Safety of Tezepelumab in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) (COURSE)
NCT04039113

 

Immunological Basis for Benralizumab Activity in Chronic Obstructive Pulmonary Disease (COPD)
NCT05273359

 

Video Telehealth Pulmonary Rehabilitation to Reduce Hospital Readmission in Chronic Obstructive Pulmonary Disease
NCT05119556

 

Immunological Basis for Mepolizumab Activity in COPD
NCT05320939

 

STRIVE Post-Market Registry Study
NCT04302272

 

myAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home
NCT05204888

 

Functional Lung Imaging in Patients with Respiratory Compromise Undergoing Endobronchial Valve Placement
NCT05204875

 

Efficacy and Safety of Tozorakimab (MEDI3506) in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations. (TITANIA)
NCT05158387

 

A Study to Evaluate the Efficacy and Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
NCT05037929

A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
NCT05321069

 

A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)
NCT05321082

 

Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry (IPF/ILDPRO)
NCT01915511

 

Autoantibody Reduction for Acute Exacerbations of Idiopathic Pulmonary Fibrosis (STRIVE-IPF)
NCT03286556

 

GKT137831 in IPF Patients With Idiopathic Pulmonary Fibrosis (GKT137831)
NCT03865927

 

Prospective Treatment Efficacy in IPF Using Genotype for Nac Selection (PRECISIONS) Trial (PRECISIONS)
NCT04300920

 

Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis (TETON)
NCT04708782

 

A Randomized, Double Blind, Placebo-controlled, study to investigate the safety, pharmacokinetics and pharmacodynamics of CSL312 in Subjects with Idiopathic Pulmonary Fibrosis
NCT05130970

 

A Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects With Idiopathic Pulmonary Fibrosis
NCT05032066

 

Trial of Therapeutic Hypothermia in Patients With ARDS (CHILL)

DECAMP 1 PLUS: Prediction of Lung Cancer Using Noninvasive Biomarkers

Comparison of Two- Versus Three-antibiotic Therapy for Pulmonary Mycobacterium Avium Complex Disease (MAC2v3)

Clofazimine in the Treatment of Pulmonary Mycobacterium Avium Complex (MAC)
NCT02968212

The PEERLESS Study (PEERLESS)

A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE (MAGNOLIA)
NCT05171075

A Study to Assess Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis at Risk for Pulmonary Hypertension (REBUILD)

A Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension (ELEVATE 2)
NCT04712669

A Dose Escalation Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis or Sarcoidosis (Pulse-PHPF-002)

A Study to Assess the Efficacy and Safety of Namilumab in Participants With Chronic Pulmonary Sarcoidosis (RESOLVE-Lung)
NCT05314517

A Study to Evaluate the Efficacy and Safety of Dupilumab in Participants With Allergic Bronchopulmonary Aspergillosis (ABPA) (LIBERTY ABPA AIRED)
NCT04442269

 

American Lung Association (ALA) Lung Health Cohort
NCT04543461

 

SPIROMICS Study of Early COPD Progression (SOURCE) (SOURCE)
NCT05033990

 

A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE (ASTER)

For more information about clinical research trials at the Temple Lung Center,
email breathe@tuhs.temple.edu or call 215-707-1359.